St. Jude's Departure From AdvaMed Highlights Inherent Industry Tensions
This article was originally published in The Gray Sheet
Executive Summary
St. Jude Medical CEO Daniel Starks has resigned from AdvaMed's board of directors and the company has left the organization, citing "strong dissent" over how to respond to proposed medical device fees in pending health reform legislation
You may also be interested in...
China Is Top International Priority For AdvaMed's New Chairman
AdvaMed's new chairman, Jim Mazzo, cites regulatory roadblocks in China as the most important international marketing issue facing U.S. device manufacturers
China Is Top International Priority For AdvaMed's New Chairman
AdvaMed's new chairman, Jim Mazzo, cites regulatory roadblocks in China as the most important international marketing issue facing U.S. device manufacturers
With Device Tax Seeming Inevitable, Groups Align On Small-Firm Protections
Groups representing the device industry have aligned to push an amendment to the Senate health care reform bill to exempt more pre- and low-profit companies from the proposed $20 billion device tax